Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | PTPRC | P08575 | 1/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2912882 | 0.84 | MAPK14 (0.62) | MEN1KMT2AMAPTL3MBTL1MAPK14 | |
| SCHEMBL2347126 | 0.83 | CYP17A1 (0.47) | MAPTMAPK14 | |
| SCHEMBL2912590 | 0.82 | MAPK14 (0.50) | MAPK14 | |
| SCHEMBL2912653 | 0.81 | IP6K1 (0.49) | MEN1KMT2AMAPTL3MBTL1MAPK14 | |
| SCHEMBL2348556 | 0.81 | MAPK14 (0.67) | MEN1KMT2AMAPTMAPK14 | |
| SCHEMBL7332862 | 0.80 | L3MBTL1 (0.76) | MEN1KMT2AMAPTL3MBTL1LMNA | |
| SCHEMBL2914161 | 0.78 | MAPK14 (0.67) | MAPTPTPRCMAPK14 | |
| SCHEMBL2911571 | 0.78 | MAPK14 (0.51) | MAPK14 | |
| SCHEMBL2349750 | 0.78 | MAPK14 (0.69) | MAPK14 | |
| SCHEMBL2914638 | 0.78 | MITF (0.64) | MEN1KMT2AMAPTPTPN1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940786-B1 | BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C | ARROW THERAPEUTICS LTD (GB) | 2010-08-18 | — | — | EP | disclosed |
| US-20080255105-A1 | Biphenyl Derivatives and Their Use in Treating Hepatitis C | ARROW THERAPEUTICS LIMITED (GB) | 2008-10-16 | — | — | US | disclosed |
| EP-1940786-A1 | BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C | Arrow Therapeutics Limited (GB) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007031791-A1 | BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C | ARROW THERAPEUTICS LIMITED (GB) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255105-A1 | Biphenyl Derivatives and Their Use in Treating Hepatitis C | NR4A1, NR0B1, NR1H4 | MEN1 3163/4885KMT2A 3804/4885MAPT 4798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.